KURA Kura Oncology Inc.

16.44
-0.17  -1%
Previous Close 16.61
Open 16.63
Price To Book 3.02
Market Cap 743,333,285
Shares 45,214,920
Volume 117,667
Short Ratio
Av. Daily Volume 268,141

NewsSee all news

  1. Kura Oncology Doses First Patient in Phase 1 Clinical Trial of Menin-MLL Inhibitor KO-539 in Acute Myeloid Leukemia

    – KO-539 is a first-in-class small molecule inhibitor of the menin-MLL interaction – – First-in-human trial to determine MTD, expand to genetic subgroups such as NPM1 – SAN DIEGO, Sept. 16, 2019 (GLOBE NEWSWIRE) --

  2. Kura Oncology Announces Positive Phase 2 Trial of Tipifarnib in HRAS Mutant Urothelial Carcinoma

    – Confirmed objective responses achieved in five of 13 evaluable patients – – Primary endpoint met prior to completion of enrollment with four patients experiencing progression-free survival greater than 6 months – –

  3. Kura Oncology to Participate in Two Upcoming Investor Conferences

    SAN DIEGO, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 1H 2020.
Tipifarnib
Chronic myelomonocytic leukemia (CMML) - cancer
Phase 2 data due 4Q 2019.
Tipifarnib
Relapsed or refractory peripheral T-cell lymphoma
Phase 2 data due 4Q 2019.
Tipifarnib - (AIM-HN/SEQ-HN)
Head and neck squamous cell carcinomas (HNSCC)
Phase 1 data due by the end of 2019.
KO-947
Solid tumors
Phase 2 data due 4Q 2019.
Tipifarnib - KO-TIP-001
Head and Neck Cancer With HRAS Mutations
Phase 1 initiation of dosing announced September 16, 2019.
KO-539
Relapsed or refractory acute myeloid leukemia (AML)
Phase 2 data noted objective responses achieved in 5/13 patients.
Tipifarnib
HRAS Mutant Urothelial Carcinoma

Latest News

  1. Kura Oncology Doses First Patient in Phase 1 Clinical Trial of Menin-MLL Inhibitor KO-539 in Acute Myeloid Leukemia

    – KO-539 is a first-in-class small molecule inhibitor of the menin-MLL interaction – – First-in-human trial to determine MTD, expand to genetic subgroups such as NPM1 – SAN DIEGO, Sept. 16, 2019 (GLOBE NEWSWIRE) --

  2. Kura Oncology Announces Positive Phase 2 Trial of Tipifarnib in HRAS Mutant Urothelial Carcinoma

    – Confirmed objective responses achieved in five of 13 evaluable patients – – Primary endpoint met prior to completion of enrollment with four patients experiencing progression-free survival greater than 6 months – –

  3. Kura Oncology to Participate in Two Upcoming Investor Conferences

    SAN DIEGO, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced